Debiopharm and Allergan agree to transition the rights to commercialize Trelstar to new licensees. Debiopharm is in advanced discussion with a potential partner in Canada and is engaged in a bidding process for US rights
LAUSANNE, Switzerland, Jan. 7, 2019 /CNW/ - Debiopharm Group™ (Debiopharm - http://www.debiopharm.com), a Swiss-based global biopharmaceutical company, today announced an agreement with Allergan to initiate a transition process for Trelstar intended to lead to new licensees taking over the commercialization of Trelstar in the US and Canada and the termination of Allergan's partnership with Debiopharm for strategic reasons.
Under the terms of the agreement, Debiopharm is allowed to seek new licensees in the Territory while Allergan will maintain commercial efforts to promote the Product and respond to patients' needs until new partners are secured.
Allergan will be actively supporting Debiopharm in the transfer to the new licensees, and in the meantime will continue its current commercialization activities for Trelstar. Both Debiopharm and Allergan intend to provide undisrupted access to Trelstar for patients and providers.
"We are now looking for new partners with a strong footprint in urology to continue to bring Trelstar to the patients. We thank Allergan for supporting a smooth transition with our new partner in both the US and Canada," explained Thierry Mauvernay, President & Delegate of the Board, Debiopharm Group.
Triptorelin is an agonist analogue of the natural gonadotropin-releasing hormone (GnRH). Debiopharm has developed three sustained-release formulations (1, 3 and 6 months) of triptorelin pamoate. Triptorelin was first registered in France in 1986, is currently marketed in more than 80 countries and is market leader in many territories worldwide. In the US, triptorelin is registered for Prostate Cancer as Trelstar®.
About Debiopharm Group
Debiopharm Group™ is a Swiss-headquartered global biopharmaceutical group including five companies active in the life science areas of drug development, GMP manufacturing of proprietary drugs, diagnostic tools and investment management. Debiopharm focuses on the development of prescription drugs that target unmet medical needs. The company in-licenses and develops promising drug candidates. The products are commercialized by pharmaceutical out-licensing partners to give access to the largest number of patients worldwide.
For more information, please visit http://www.debiopharm.com
SOURCE Debiopharm International SA
For further information: Debiopharm International SA Contact: Fabrice Paradies, Director Industrial Business Development & Global Commercial Alliances, firstname.lastname@example.org, Tel: +41-(0)21-321-01-11; Christelle von Büren, Communication Coordinator, email@example.com, Tel: +41-(0)21-321-01-11